Wayne State University, Division of Neuroimmunology, Department of Neurology, Detroit, MI 48201, USA.
Expert Opin Pharmacother. 2010 Dec;11(17):2869-78. doi: 10.1517/14656566.2010.508070. Epub 2010 Aug 5.
Multiple sclerosis (MS) is a neurologic disease that is the most common nontraumatic cause of serious disability in young adults.
We discuss the natural history of the disease, methods of measuring disease activity and burden, and cellular and molecular mechanisms of damage, in particular recent advances. These imply new therapeutic targets, which are beginning to be tested in animal models of MS as well as in patients.
The reader will learn about some recent advances in understanding MS, especially the evolution from an inflammatory phase to a neurodegenerative phase, which have different therapeutic approaches.
MS has a long-term course of accumulating deficit in which neuroinflammation evolves into neurodegeneration, which require different treatment strategies - immune modulation and neuroprotection. Neuroprotective strategies are still under development.
多发性硬化症（MS）是一种神经系统疾病，是年轻人中最常见的非外伤性严重残疾原因。
我们讨论了疾病的自然史、衡量疾病活动和负担的方法，以及细胞和分子损伤机制，特别是最近的进展。这些进展暗示了新的治疗靶点，这些靶点已经开始在 MS 的动物模型以及患者中进行测试。
读者将了解到一些关于 MS 的最新进展，特别是从炎症阶段到神经退行性阶段的演变，这需要不同的治疗方法。
MS 具有长期的累积缺陷过程，其中神经炎症演变为神经退行性变，这需要不同的治疗策略——免疫调节和神经保护。神经保护策略仍在开发中。
